The molecular evidence behind the adjunct use of anticoagulants and chemotherapy in pancreatic cancer treatment: A new role for anticoagulants?
G Lababidi, N Wahoud, L Ghandour, N Moukalled… - Human Gene, 2024 - Elsevier
Pancreatic cancers include highly aggressive forms of neoplasms, with limited treatment
options and high mortality rates. Recent studies have highlighted various molecular …
options and high mortality rates. Recent studies have highlighted various molecular …
[HTML][HTML] Commonly prescribed anticoagulants exert anticancer effects in oral squamous cell carcinoma cells in vitro
Simple Summary Oral squamous cell carcinoma (OSCC) is the sixth most common cancer
worldwide with 840,000 new cases and 420,000 deaths in 2020. Anticoagulants are widely …
worldwide with 840,000 new cases and 420,000 deaths in 2020. Anticoagulants are widely …
Development of a thrombin generation test in cultured endothelial cells: Evaluation of the prothrombotic effects of antiphospholipid antibodies
Introduction Circulating antiphospholipid antibodies (APL) induce vascular injury and
endothelial dysfunction, which are associated with thrombotic events and/or fetal loss. We …
endothelial dysfunction, which are associated with thrombotic events and/or fetal loss. We …
Thrombin generation increasing with age and decreasing with use of heparin indicated by calibrated automated thrombogram conducted in Chinese
WU Jun, HR Zhao, HY Zhang, YL Ge… - Biomedical and …, 2014 - Elsevier
Abstract Objective Calibrated Automated Thrombogram (CAT) is a test to monitor the
generation of thrombin. It can be described by four parameters: lag time, peak thrombin …
generation of thrombin. It can be described by four parameters: lag time, peak thrombin …
In Vitro Study of Synergic Effect of Cisplatin and Low Molecular Weight Heparin on Oral Squamous Cell Carcinoma
F Camacho-Alonso, T Gómez-Albentosa… - Frontiers in …, 2020 - frontiersin.org
Objectives To evaluate the possible synergic effect of cisplatin and low molecular weight
heparin (LMWH) on oral squamous cell carcinoma (OSCC). Materials and Methods Cisplatin …
heparin (LMWH) on oral squamous cell carcinoma (OSCC). Materials and Methods Cisplatin …
Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin
A Rousseau, P Van Dreden, E Mbemba, I Elalamy… - Thrombosis …, 2015 - Elsevier
Introduction Cancer cells may alter the efficiency of the antithrombotic agents. To explore
this possibility, the present study compared the capacity of the LMWH enoxaparin and the …
this possibility, the present study compared the capacity of the LMWH enoxaparin and the …
The antithrombotic potential of tinzaparin and enoxaparin upon thrombin generation triggered in vitro by human ovarian cancer cells IGROV1
M Sassi, T Chakroun, E Mbemba… - Clinical and Applied …, 2017 - journals.sagepub.com
Background: A documented relationship between ovarian cancer and thrombosis does exist.
Low-molecular-weight heparins (LMWHs) are cornerstone drugs in the primary prevention …
Low-molecular-weight heparins (LMWHs) are cornerstone drugs in the primary prevention …
[HTML][HTML] In Surgical Colon Cancer Patients Extended-Duration Thromboprophylaxis (30 days) with the Highest Dose of Tinzaparin (4,500 IU sc/qd) Normalizes the …
Background/Purpose: In colon cancer (CC) patients preoperative (pre-op) levels of VEGF-A
165 (VEGF) is a strong predictor for disease recurrence. Elevated postoperative (post-op) …
165 (VEGF) is a strong predictor for disease recurrence. Elevated postoperative (post-op) …
Effects of enoxaparin emulsion on dimethylbenzanthracene-induced breast cancer in female rats
M Bolandpayeh, M Hassanpour-Ezzati… - Research in Molecular …, 2017 - knepublishing.com
Introduction: Enoxaparin is an anticoagulant medication. Anticoagulation inhibits tumor cell-
mediated release of angiogenic proteins and diminishes angiogenic response …
mediated release of angiogenic proteins and diminishes angiogenic response …
Characterization of the Antithrombotic Fingerprint of the Branded and Copies of the Low-Molecular-Weight Enoxaparin Using Thrombin Generation Assay
GT Gerotziafas, A Rouseau… - Clinical and Applied …, 2015 - journals.sagepub.com
Background: The patent protection of low-molecular-weight heparins (LMWHs) expired, so
the definition of criteria for the biological similarity between LMWH copies and the original …
the definition of criteria for the biological similarity between LMWH copies and the original …